S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel

Compare Stocks

Date Range: 

 Johnson & JohnsonRochePfizerEli Lilly andNovo Nordisk A/S
SymbolNYSE:JNJOTCMKTS:RHHBYNYSE:PFENYSE:LLYNYSE:NVO
Price Information
Current Price$164.36$46.01$43.94$231.68$100.70
50-Day Moving Average$171.71$48.49$45.45$251.32$99.03
52-Week Low$133.65$39.72$33.36$129.21$63.22
52-Week High$179.92$51.05$51.86$275.87$107.24
MarketRank™
Overall Score2.82.02.72.71.4
Analysis Score2.42.12.12.50.0
Community Score4.44.34.84.84.0
Dividend Score4.22.53.32.51.7
Ownership Score1.70.02.52.50.0
Earnings & Valuation Score1.31.30.61.31.3
Analyst Ratings
Consensus RecommendationBuyHoldHoldBuyHold
Consensus Price Target$190.38$46.42$43.33$250.81N/A
% Upside from Price Target15.83% upside0.89% upside-1.38% downside8.26% upsideN/A
Trade Information
Market Cap$432.67 billion$314.25 billion$246.36 billion$222.19 billion$237.13 billion
Beta0.710.340.740.250.41
Average Volume7,089,9941,474,40030,753,8523,501,992988,756
Sales & Book Value
Annual Revenue$82.58 billion$64.54 billion$41.91 billion$24.54 billion$19.45 billion
Price / Sales5.244.875.889.0512.19
Cashflow$10.71 per share$3.34 per share$3.00 per share$8.66 per share$3.15 per share
Price / Cash15.3413.7814.6626.7631.95
Book Value$24.04 per share$6.19 per share$11.42 per share$6.09 per share$4.12 per share
Price / Book6.847.433.8538.0424.44
Profitability
Net Income$14.71 billion$15.25 billion$9.62 billion$6.19 billion$6.46 billion
EPS$8.03$2.65$2.22$7.93$2.76
Trailing P/E Ratio24.7217.3618.8634.7332.91
Forward P/E Ratio15.9616.4312.8927.2928.53
P/E Growth2.232.321.581.862.81
Net Margins19.92%N/A23.06%22.71%34.17%
Return on Equity (ROE)37.06%N/A26.49%119.12%72.72%
Return on Assets (ROA)14.04%N/A10.73%15.81%30.72%
Dividend
Annual Payout$4.24$0.77$1.56$3.40$0.77
Dividend Yield2.58%1.67%3.55%1.47%0.76%
Three-Year Dividend Growth19.88%N/A-10.94%42.31%13.65%
Payout Ratio52.80%29.06%70.27%42.88%27.90%
Years of Consecutive Dividend Growth59 YearsN/A1 Years1 YearsN/A
Debt
Debt-to-Equity Ratio0.44%0.26%0.50%2.21%0.19%
Current Ratio1.39%1.30%1.37%1.15%1.06%
Quick Ratio1.13%1.01%1.12%0.89%0.80%
Ownership Information
Institutional Ownership Percentage67.29%0.32%64.93%81.65%5.58%
Insider Ownership Percentage0.30%N/A0.05%0.13%0.07%
Miscellaneous
Employees134,500101,46578,50035,00045,323
Shares Outstanding2.63 billion6.83 billion5.61 billion959.03 million2.35 billion
Next Earnings Date10/19/2021 (Confirmed)N/A10/26/2021 (Estimated)10/26/2021 (Confirmed)10/29/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Novo Nordisk To Pay $100M To Settle Investor Class ActionNovo Nordisk To Pay $100M To Settle Investor Class Action
law360.com - September 25 at 12:08 AM
Facing class action lawsuit over insulin pricing, Novo Nordisk inks $100M settlement with disgruntled investorsFacing class action lawsuit over insulin pricing, Novo Nordisk inks $100M settlement with disgruntled investors
fiercepharma.com - September 24 at 7:00 PM
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid ChoiceLooking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
finance.yahoo.com - September 24 at 7:00 PM
Novo Nordisk A/S Relieves Reporting HeadachesNovo Nordisk A/S Relieves Reporting Headaches
workiva.com - September 24 at 2:00 PM
BRIEF-Novo Nordisk To Pay $100 Mln In Settlement AgreementBRIEF-Novo Nordisk To Pay $100 Mln In Settlement Agreement
news.trust.org - September 24 at 2:00 PM
The Novo Nordisk Foundation funds the worlds first interdisciplinary research center to convert CO2 in the atmosphere into sustainable raw materialsThe Novo Nordisk Foundation funds the world's first interdisciplinary research center to convert CO2 in the atmosphere into sustainable raw materials
finance.yahoo.com - September 22 at 7:54 AM
CVS Health, Novo Nordisk Inc. join forces to provide enhanced, personalized support for obesity in retail settingsCVS Health, Novo Nordisk Inc. join forces to provide enhanced, personalized support for obesity in retail settings
publicnow.com - September 17 at 1:54 PM
CVS Health, Novo Nordisk Inc. join forces to provide enhanced, personalized support for obesity in retail settingsCVS Health, Novo Nordisk Inc. join forces to provide enhanced, personalized support for obesity in retail settings
publicnow.com - September 17 at 1:54 PM
Novo Nordisk, Broad Institute Partner to Uncover Genetic Links to DiseaseNovo Nordisk, Broad Institute Partner to Uncover Genetic Links to Disease
pharmalive.com - September 17 at 1:54 PM
Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetesNovo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
massdevice.com - September 15 at 1:39 PM
Interesting NVO Put And Call Options For November 19thInteresting NVO Put And Call Options For November 19th
nasdaq.com - September 15 at 1:39 PM
USTA Foundation Awards $60,000 To Youth Players Through Novo Nordisk Donnelly ScholarshipUSTA Foundation Awards $60,000 To Youth Players Through Novo Nordisk Donnelly Scholarship
tennis-tourtalk.com - September 11 at 6:41 PM
Semaglutide prescription to be restricted to endocrinologists only: CDSCO panel tells Novo NordiskSemaglutide prescription to be restricted to endocrinologists only: CDSCO panel tells Novo Nordisk
medicaldialogues.in - September 11 at 7:23 AM
Heres Why Novo Nordisk (NVO) is a Strong Growth StockHere's Why Novo Nordisk (NVO) is a Strong Growth Stock
finance.yahoo.com - September 9 at 6:09 PM
Indonesia joins Novo Nordisk and partners in the global Changing Diabetes® in Children partnershipIndonesia joins Novo Nordisk and partners in the global Changing Diabetes® in Children partnership
scandasia.com - September 8 at 3:31 AM
Novo Nordisk A/S (NYSE:NVO) Rating Reiterated by Berenberg BankNovo Nordisk A/S (NYSE:NVO) Rating Reiterated by Berenberg Bank
americanbankingnews.com - September 3 at 2:34 PM
Novo Nordisk A/S (NYSE:NVO) Stock Rating Reaffirmed by Berenberg BankNovo Nordisk A/S (NYSE:NVO) Stock Rating Reaffirmed by Berenberg Bank
marketbeat.com - September 3 at 1:18 PM
MIT, Novo Nordisk advance oral biologics delivery projectMIT, Novo Nordisk advance oral biologics delivery project
fiercepharma.com - August 31 at 3:58 PM
House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On Unacceptably High Insulin PricesHouse Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices
finance.yahoo.com - August 20 at 5:58 PM
November 2022 Options Now Available For Novo-Nordisk (NVO)November 2022 Options Now Available For Novo-Nordisk (NVO)
nasdaq.com - August 18 at 4:00 PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021
finance.yahoo.com - August 11 at 12:41 PM
Novo Nordisk CEO on product pricing: Our numbers are declining year-on-yearNovo Nordisk CEO on product pricing: Our numbers are 'declining year-on-year'
finance.yahoo.com - August 11 at 12:41 PM
LRT Capital on Novo Nordisk (NVO): “We Believe this to be Highly Attractive”LRT Capital on Novo Nordisk (NVO): “We Believe this to be Highly Attractive”
finance.yahoo.com - August 10 at 3:01 PM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021
finance.yahoo.com - August 10 at 10:00 AM
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021
finance.yahoo.com - August 9 at 12:59 PM
Here Are the Winners of Cowens Big Pharma R&D ShowdownHere Are the Winners of Cowen's Big Pharma R&D Showdown
finance.yahoo.com - August 7 at 12:48 PM
3 European Stocks to Buy for International Exposure (NVO)3 European Stocks to Buy for International Exposure (NVO)
marketbeat.com - May 25 at 8:05 PM
DateCompanyBrokerageAction
9/24/2021Eli Lilly andJPMorgan Chase & Co.
Reiterated Rating
9/20/2021PfizerSVB Leerink
Boost Price Target
9/14/2021PfizerSVB Leerink
Reiterated Rating
9/13/2021PfizerJPMorgan Chase & Co.
Boost Price Target
9/7/2021Johnson & JohnsonMorgan Stanley
Downgrade
9/7/2021RocheUBS Group
Reiterated Rating
9/3/2021Novo Nordisk A/SBerenberg Bank
Reiterated Rating
8/30/2021Eli Lilly andCowen
Boost Price Target
8/23/2021Novo Nordisk A/SCredit Suisse Group
Reiterated Rating
8/23/2021Novo Nordisk A/SCitigroup
Reiterated Rating
8/17/2021Novo Nordisk A/SUBS Group
Reiterated Rating
8/11/2021Novo Nordisk A/SMorgan Stanley
Reiterated Rating
8/9/2021Eli Lilly andArgus
Boost Price Target
8/6/2021Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
8/5/2021Eli Lilly andDZ Bank
Upgrade
8/5/2021Novo Nordisk A/SBarclays
Reiterated Rating
8/5/2021Novo Nordisk A/SBank of America
Upgrade
8/5/2021Novo Nordisk A/SDNB Markets
Upgrade
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Boost Price Target
8/3/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
8/2/2021RocheJPMorgan Chase & Co.
Reiterated Rating
7/30/2021PfizerMizuho
Boost Price Target
7/29/2021Johnson & JohnsonSVB Leerink
Reiterated Rating
7/29/2021PfizerThe Goldman Sachs Group
Set Price Target
7/29/2021PfizerMorgan Stanley
Boost Price Target
7/29/2021PfizerRoyal Bank of Canada
Set Price Target
7/29/2021PfizerSVB Leerink
Boost Price Target
7/27/2021RocheSociete Generale
Reiterated Rating
7/27/2021PfizerTruist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/23/2021RocheBarclays
Set Price Target
7/21/2021Johnson & JohnsonSVB Leerink
Reiterated Rating
7/21/2021RocheCowen
Initiated Coverage
7/19/2021RocheUBS Group
Reiterated Rating
7/19/2021Novo Nordisk A/SBarclays
Reiterated Rating
7/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/14/2021RocheJefferies Financial Group
Upgrade
7/8/2021RocheDeutsche Bank Aktiengesellschaft
Upgrade
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021PfizerRoyal Bank of Canada
Boost Price Target
6/15/2021PfizerBerenberg Bank
Reiterated Rating
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021RocheBerenberg Bank
Reiterated Rating
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/10/2021RocheMorgan Stanley
Reiterated Rating
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/7/2021Johnson & JohnsonCredit Suisse Group
Set Price Target
6/2/2021RocheSociete Generale
Downgrade
6/1/2021Johnson & JohnsonCredit Suisse Group
Set Price Target
5/28/2021Johnson & JohnsonMorgan Stanley
Initiated Coverage
5/24/2021PfizerJPMorgan Chase & Co.
Set Price Target
5/24/2021PfizerThe Goldman Sachs Group
Set Price Target
5/13/2021PfizerThe Goldman Sachs Group
Reiterated Rating
5/12/2021PfizerMizuho
Reiterated Rating
5/10/2021PfizerMorgan Stanley
Boost Price Target
5/6/2021PfizerMizuho
Downgrade
5/5/2021PfizerSVB Leerink
Boost Price Target
5/5/2021PfizerJPMorgan Chase & Co.
Boost Price Target
5/5/2021PfizerBarclays
Boost Price Target
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/7/2021PfizerRoyal Bank of Canada
Initiated Coverage
4/6/2021PfizerThe Goldman Sachs Group
Set Price Target
3/31/2021PfizerThe Goldman Sachs Group
Set Price Target
3/26/2021PfizerSVB Leerink
Lower Price Target
3/23/2021PfizerBerenberg Bank
Reiterated Rating
3/16/2021RocheJefferies Financial Group
Downgrade
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/5/2021RocheErste Group
Downgrade
2/25/2021RocheBerenberg Bank
Reiterated Rating
2/24/2021RocheMorgan Stanley
Reiterated Rating
2/17/2021RocheUBS Group
Downgrade
2/12/2021Eli Lilly andCowen
Boost Price Target
2/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
2/10/2021RocheJPMorgan Chase & Co.
Reiterated Rating
2/4/2021RocheOddo Bhf
Downgrade
2/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
2/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
2/1/2021Eli Lilly andTruist
Boost Price Target
1/27/2021Johnson & JohnsonJPMorgan Chase & Co.
Boost Price Target
1/27/2021Johnson & JohnsonCredit Suisse Group
Boost Price Target
1/27/2021Johnson & JohnsonRaymond James
Boost Price Target
1/27/2021Johnson & JohnsonCowen
Boost Price Target
1/27/2021Johnson & JohnsonMorgan Stanley
Boost Price Target
1/27/2021Johnson & JohnsonSVB Leerink
Boost Price Target
1/27/2021Johnson & JohnsonWells Fargo & Company
Boost Price Target
1/26/2021Johnson & JohnsonCantor Fitzgerald
Boost Price Target
1/22/2021RocheBarclays
Reiterated Rating
1/20/2021Novo Nordisk A/SCredit Suisse Group
Downgrade
1/15/2021RocheDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/12/2021RocheUBS Group
Reiterated Rating
1/8/2021RocheMorgan Stanley
Downgrade
1/4/2021RocheJPMorgan Chase & Co.
Downgrade
12/15/2020Johnson & JohnsonMorgan Stanley
Boost Price Target
11/27/2020RocheUBS Group
Reiterated Rating
11/20/2020Johnson & JohnsonRaymond James
Reiterated Rating
11/12/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
11/6/2020Novo Nordisk A/SMorgan Stanley
Downgrade
11/3/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
10/16/2020RocheUBS Group
Reiterated Rating
10/15/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
10/14/2020Johnson & JohnsonCredit Suisse Group
Boost Price Target
10/14/2020Johnson & JohnsonCantor Fitzgerald
Boost Price Target
10/13/2020Johnson & JohnsonCredit Suisse Group
Set Price Target
9/29/2020Novo Nordisk A/SBerenberg Bank
Initiated Coverage
9/4/2020Johnson & JohnsonCredit Suisse Group
Reiterated Rating
8/19/2020Johnson & JohnsonStifel Nicolaus
Downgrade
8/18/2020Novo Nordisk A/SUBS Group
Reiterated Rating
8/3/2020Johnson & JohnsonCantor Fitzgerald
Reiterated Rating
8/3/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
7/20/2020Johnson & JohnsonBank of America
Reiterated Rating
7/20/2020Johnson & JohnsonIndependent Research
Upgrade
7/17/2020Johnson & JohnsonRaymond James
Boost Price Target
7/6/2020Novo Nordisk A/SBank of America
Downgrade
5/18/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
(Data available from 9/25/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.